Today: 21 July 2026
Browse Category

Pharmaceutical Industry 6 May 2026 - 18 July 2026

Vera Therapeutics (NASDAQ:VERA) stock up; Trutakna approval shifts attention to Q3 kidney data

Vera Therapeutics (NASDAQ:VERA) stock up; Trutakna approval shifts attention to Q3 kidney data

Vera Therapeutics, Inc. finished up 7.05% at $42.96 on Tuesday after U.S. regulators approved Trutakna. The bigger investor focus was on the size of the bid. With 71.78 million shares outstanding from Google Finance and a $2.83 move on the day, that comes out to roughly $203 million more in equity value added. That’s around a third of Vera’s last reported cash, and not a big reset for a $3.08 billion biotech that’s now swapped FDA risk for launch risk.
7 July 2026
··
Apotex Health rises on TSX after IPO block grows by C$620 million following Cumberland deal

Apotex Health rises on TSX after IPO block grows by C$620 million following Cumberland deal

Apotex Health Corp. climbed 4.75% Friday to C$33.95, a new record close since its June debut. Canada’s S&P/TSX Composite Index also gained, finishing up 0.9% at 35,274.84. Trading volume was light for Apotex. Just 146,773 shares traded, well below its 65-day average, though the stock did hit a fresh intraday high at C$34.38.
3 July 2026
····
Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up

Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up

Outlook Therapeutics shares surged Wednesday as the stock once again drew regulatory-timer trades after the company filed its newest FDA application for ONS-5010/LYTENAVA, its candidate for wet age-related macular degeneration. The stock was last quoted near $0.89, up about 26% from Tuesday's close, with shares trading between $0.6853 and $0.8999 and volume near 21.9 million shares.
10 June 2026
··
Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax shares dropped hard Tuesday, despite positive late-stage trial results for its obefazimod drug. Investors focused on reported cancer and dysplasia cases in patients on the higher dose. The stock traded at 63.10 euros on Euronext Paris, well below Monday’s closing price of 111.80 euros, after touching 62.80 euros earlier. Over in the U.S., its Nasdaq ADRs were last at $72.86, down some 44% late in the session.
2 June 2026
····
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio shares were active before the Nasdaq bell on Monday after the company said five U.S. patents will protect its Anktiva-plus-BCG bladder cancer treatment into at least 2035. This statement followed Friday’s announcement of an exclusive U.S. supply deal with Japan BCG Laboratory. The stock last traded at $7.97, unchanged from Friday’s close, when it slipped 2.2% on volume of 11.3 million shares.
18 May 2026
··
Avalo Therapeutics Stock Jumps As $375 Million Raise Follows Phase 2 HS Trial Win

Avalo Therapeutics Stock Jumps As $375 Million Raise Follows Phase 2 HS Trial Win

Late Tuesday, Avalo Therapeutics Inc. locked in a $375 million public offering—just hours after rolling out upbeat Phase 2 results for abdakibart. Riding the surge of interest tied to its hidradenitis suppurativa program, the company aims to fund its looming Phase 3 plans. Avalo is set to offer 19.73 million shares at $17.75 apiece, along with pre-funded warrants for another 1.4 million shares at $17.749 each. Closing is slated for May 7, pending standard closing conditions.
6 May 2026
··
1 2 3 … 10
Go toTop